<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36073566</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0304-4920</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>The Chinese journal of physiology</Title><ISOAbbreviation>Chin J Physiol</ISOAbbreviation></Journal><ArticleTitle>Prazosin improves neurogenic acute heart failure through downregulation of fibroblast growth factor 23 in rat hearts.</ArticleTitle><Pagination><StartPage>179</StartPage><EndPage>186</EndPage><MedlinePgn>179-186</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/cjp.cjp_9_22</ELocationID><Abstract><AbstractText>Bilateral nucleus tractus solitarii (NTS) lesions, possibly caused by enterovirus 71 infection, cause severe neurogenic hypertension, leading to acute heart failure (HF), pulmonary edema, and death within hours. Alpha-adrenergic blockers attenuate blood pressure and ameliorate HF and pulmonary edema, thereby prolonging survival time. However, the molecular mechanisms of these blockers are not clear. In this study, we investigated these mechanisms in a rat model of 6-hydroxydopamine (6-OHDA)-induced HF. Sprague-Dawley rats were treated with prazosin 10 min after the microinjection of 6-OHDA into the NTS. Immunohistochemistry and dihydroethidium (DHE) staining were used for analysis. In the cardiac tissue of 6-OHDA-induced HF, in situ expression of tumor necrosis factor-alpha (TNF-&#x3b1;), fibroblast growth factor-23 (FGF23), and FGF receptor 1 (FGFR1) increased, but in situ expression of Vitamin D receptor (VDR) decreased. DHE staining revealed several heart cells with high reactive oxygen species production. Prazosin treatment decreased TNF-&#x3b1;, FGF23, and FGFR1 expression in the heart of rats with 6-OHDA-induced HF. It also prevented cardiomyopathy caused by 6-OHDA-induced bilateral NTS lesions by inhibiting the FGF23-FGFR1 pathway and downregulating TNF-&#x3b1; expression. In situ, FGF23, FGFR1, VDR, superoxide, and TNF-&#x3b1; in the heart were found to be involved in acute HF in our rat model of 6-OHDA-induced bilateral NTS lesions. These findings are potentially useful for treating fatal enterovirus 71 infection-induced NTS lesions and HF.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Jun-Yen</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Wen-Hsien</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chieh-Jen</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Ching-Jiunn</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung; Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hsin-Hung</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Chin J Physiol</MedlineTA><NlmUniqueID>7804502</NlmUniqueID><ISSNLinking>0304-4920</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>62031-54-3</RegistryNumber><NameOfSubstance UI="D005346">Fibroblast Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>7Q7P4S7RRE</RegistryNumber><NameOfSubstance UI="D000089703">Fibroblast Growth Factor-23</NameOfSubstance></Chemical><Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber><NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>XM03YJ541D</RegistryNumber><NameOfSubstance UI="D011224">Prazosin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089703" MajorTopicYN="N">Fibroblast Growth Factor-23</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005346" MajorTopicYN="N">Fibroblast Growth Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011224" MajorTopicYN="N">Prazosin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011654" MajorTopicYN="Y">Pulmonary Edema</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">6-Hydroxydopamine</Keyword><Keyword MajorTopicYN="N">alpha-adrenergic blockers</Keyword><Keyword MajorTopicYN="N">anti-inflammation</Keyword><Keyword MajorTopicYN="N">cardiomyopathy</Keyword><Keyword MajorTopicYN="N">fibroblast growth factor 23</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword></KeywordList><CoiStatement>None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36073566</ArticleId><ArticleId IdType="doi">10.4103/cjp.cjp_9_22</ArticleId><ArticleId IdType="pii">ChinJPhysiol_2022_65_4_179_354800</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>